CHALLENGE:

At the time, this largest ALL trial ever for Inotuzumab Ozogamicin used to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia, had a target to enroll 292 patients in just 22 months. 

SOLUTION:

Phesi’s Trial Accelerator™ platform, driven by the world’s largest trial database, was used to: 

  • Systematically analyze over 1,000 sponsored trials with a similar design, including much smaller ‘incomparable’ trials 
  • A Gross Site Enrollment Rate (GSER) of 0.067 patients per site per month, and a Site Effectiveness Index (a measure of site activation) of 60% was forecast 
  • Phesi recommended activating 120 sites and forecast a 36 month enrollment cycle time – more accurately predicting the required trial duration

THE DATA:

IMPACT:

The use of data-driven insight to select high performing sites resulted in an enrollment cycle time of 32 months and Inotuzumab ozogamicin, sold under the brand name Besponsa®, was approved by the FDA based on the results of this pivotal trial. Besponsa® was the first approved treatment for ALL.

 

Request a demo and find out how Phesi can help
you achieve smarter trials and faster cures

 

 

Related cases
03. 14. 2023
Protocol Design and Investigator Site Selection: Type 2 Diabetes Mellitus (T2DM) Read more
03. 14. 2023
Protocol Design, Country and Investigator Site Selection: NSCLC Read more
03. 14. 2023
Protocol Optimization and Study Feasibility: Iron Overload Integrated Development Plan, Phase 1B Trial Read more
03. 14. 2023
Protocol Design and Investigator Site Selection: Phase III Osteoarthritis Pain of the Knee Trial Read more
03. 06. 2023
Protocol Design and Investigator Site Selection: Follicular Lymphoma Read more